Zovia 1/35E and Alcohol/Food Interactions
There are 8 alcohol/food/lifestyle interactions with Zovia 1 / 35E (ethinyl estradiol / ethynodiol).
Ethinyl Estradiol Caffeine
Moderate Drug Interaction
Consumer information for this interaction is not currently available.
MONITOR: Coadministration of ethinyl estradiol may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 1A2. In a study of 30 healthy volunteers administered the CYP450 1A2 substrate tizanidine, the systemic exposure (AUC) of tizanidine was 3.9 times greater in women using an oral contraceptive containing ethinyl estradiol.
MANAGEMENT: Patients should be monitored for increased adverse effects of the CYP450 1A2 substrate during concomitant use with ethinyl estradiol. Product labeling for the specific CYP450 1A2 substrate should be consulted for additional recommendations.
Ethinyl Estradiol Alcohol (Ethanol)
Minor Drug Interaction
Information for this minor interaction is available on the professional version.
Ethynodiol Alcohol (Ethanol)
Minor Drug Interaction
Information for this minor interaction is available on the professional version.
Ethinyl Estradiol Food/Lifestyle
Minor Food Interaction
Information for this minor interaction is available on the professional version.
Switch to professional interaction data
Ethinyl Estradiol High Blood Pressure (Hypertension)
Major Potential Hazard, High plausibility
estrogens - hypertension
The risk of myocardial infarction and strokes, including those associated with oral contraceptive use and some estrogen use, is increased in patients with hypertension. Moreover, estrogens (and progestogens) may elevate blood pressure and worsen the hypertension, thus compounding the risk. Clinically significant blood pressure increases have been reported during estrogen therapy, particularly in patients receiving high dosages or treated with oral contraceptive combinations having high progestational activity. These effects also increase with duration of therapy and patient age. Therapy with estrogens should be administered cautiously in patients with preexisting hypertension. Some estrogen-based therapies, such as combined hormonal contraceptives, may be contraindicated in patients with uncontrolled hypertension or hypertension with vascular disease. Patients should be monitored for changes in cardiovascular status, and their antihypertensive regimen adjusted or estrogen therapy withdrawn as necessary. In patients requiring contraception, alternative methods should be considered for those who are hypertensive, over age 35, and smoke.
Ethinyl Estradiol High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
estrogens - hyperlipidemia
Estrogens may cause adverse lipid changes. Use of estrogens has been associated with elevations in triglyceride levels, particularly in women with pre-existing hypertriglyceridemia. Discontinue therapy if elevated triglycerides lead to pancreatitis. Manage hypercholesterolemia appropriately as indicated.
Ethynodiol High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
progestogens - hyperlipidemia
Some progestogenic agents may elevate plasma LDL levels and/or lower HDL levels, although data have been inconsistent. Patients with preexisting hyperlipidemia may require closer monitoring during progestogen therapy, and adjustments made accordingly in their lipid-lowering regimen.
Ethynodiol Obesity
Minor Potential Hazard, Moderate plausibility
progestogens - weight gain
Progestogens can cause weight gain, which may be significant (as is the case with parenteral medroxyprogesterone) and undesirable in obese patients attempting to lose weight.
Switch to professional interaction data
Zovia 1/35E drug interactions
There are 498 drug interactions with Zovia 1 / 35E (ethinyl estradiol / ethynodiol).
Zovia 1/35E disease interactions
There are 20 disease interactions with Zovia 1 / 35E (ethinyl estradiol / ethynodiol) which include:
- smoking
- abnormal vaginal bleeding
- carcinomas (estrogenic)
- hypercalcemia in breast cancer
- hypertension
- thromboembolism/cardiovascular
- hepatic neoplasms
- liver disease
- thromboembolism
- angioedema
- gallbladder disease
- hyperlipidemia
- liver disease
- melasma
- depression
- fluid retention
- glucose intolerance
- thyroid function tests
- hyperlipidemia
- weight gain
More about Zovia 1 / 35E (ethinyl estradiol / ethynodiol)
- Zovia 1/35E consumer information
- Check interactions
- Compare alternatives
- Reviews (60)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: contraceptives
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.